Search results
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via Yahoo Finance· 32 minutes agoMonday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of...
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate
Investing.com· 12 hours agoModerna (NASDAQ: MRNA ) and Merck (MRK) have released new, more encouraging three-year data on their...
Dow Jones Falls, S&P Reverses Lower As Warren Buffett Stock 'Plunges' 99%; GameStop Soars Amid...
Investor's Business Daily· 34 minutes agoBoeing fared best as it rallied more than 3%. It has now climbed back above the 50-day moving...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 4 hours agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 5 hours agoAs Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on...
Medical Stock Soars On Takeover; But Merck Unmoved On $3 Billion Get
Investor's Business Daily· 5 days agoSurmodics, which makes components for medical devices and tests, agreed to a $627 million takeover...
Is Merck & Co., Inc.'s (NYSE:MRK) Recent Performance Underpinned By Weak Financials?
Simply Wall St. via Yahoo Finance· 6 days agoMerck (NYSE:MRK) has had a rough month with its share price down 1.3%. To decide if this trend could...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters via Yahoo News· 5 hours agoDetailed data on Monday from the 157-patient trial showed that after two and a half years, melanoma...
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
Reuters via AOL· 5 days ago(Reuters) -Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion,...
Competitor to Merck's Keytruda Worries Some Investors
Barrons.com· 4 days agoInvestors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming...